EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Twelve Anti‐Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta‐Analysis of Randomized Controlled Trials

Fei-Fei Chen iD, Si-Yuan Wen, Xiang-Ting Chen iD, Qian Zhang, Pan Tao, Chi Meng, Jing Huang, Wei Chen, Chang-Qing Zhou

European Journal of Neurology · 2025

DOI: 10.1111/ene.70329 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Fei-Fei Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Bishan Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Anti-Dyskinesia Agents, Antiparkinson Agents, Dyskinesia, Drug-Induced, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No comparative evaluations of anti‐dyskinetic drugs to mitigate levodopa‐induced dyskinesia (LID) and OFF time have been performed; head‐to‐head anti‐dyskinetic trials are unlikely to be funded. We sought to compare the efficacy, tolerability, and safety of 12 anti‐dyskinetic drugs for peak‐dose dyskinesia and OFF time through a Bayesian network meta‐analysis.

Methods

A network meta‐analysis (NMA) was conducted for randomized controlled trials (RCTs) searched through the databases of MEDLINE, Embase, Cochrane Controlled Register of Controlled Trials from incipiency to January 2025. The main endpoints were the Unified Dyskinesia Rating Scale (UDysRS), modified Abnormal Involuntary Movement Scale, or the Unified Parkinson's Disease Rating Scale IV score for LID and the number of hours of OFF time in a standardized OFF–ON diary for OFF time reduction.

Results

Twenty‐one RCTs were included in the analysis. The surface under the cumulative ranking curve (SUCRA) indicated that amantadine extended‐release (ER) was associated with the largest improvement in the UDysRS (0.934), followed by amantadine immediate‐release (IR) (0.680). For OFF time reduction, amantadine IR (0.902) and amantadine ER (0.833) were the two best treatments compared with foliglurax (0.526), mavoglurant (0.464) and sarizotan (0.012). Fipamezole ranked first in overall withdrawals (0.812). Amantadine ER ranked first in withdrawals due to adverse events (AEs) and the incidences of AEs (≥ 1 AEs) (0.900 and 0.887).

Conclusions

Amantadine ER improved dyskinesia significantly versus amantadine IR. Both formulations of amantadine were superior as OFF time‐reducing agents compared to other anti‐dyskinetic drugs, whereas amantadine IR non‐significantly reduced OFF time versus amantadine ER.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Dyskinesia AgentsAntiparkinson AgentsDyskinesia, Drug-InducedParkinson DiseaseHumansAmantadineBayes TheoremLevodopaRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Parkinson diseaseamantadineclozapinedyskinesianetwork meta‐analysis

Substanzen

AmantadineAnti-Dyskinesia AgentsAntiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • Department of Neurology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
  • Departments of General Practice, The Affiliated Suzhou Hospital of Nanjing Medical University (Suzhou Municipal Hospital), Suzhou, Jiangsu, China.
  • Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Fei-Fei Chen, Xiang-Ting Chen

Zitieren

APA

Chen, F. F., Wen, S. Y., Chen, X. T., Zhang, Q., Tao, P., Meng, C., Huang, J., Chen, W., & Zhou, C. Q. (2025). Efficacy and Safety of Twelve Anti‐Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta‐Analysis of Randomized Controlled Trials. European Journal of Neurology. https://doi.org/10.1111/ene.70329

Vancouver

Chen FF, Wen SY, Chen XT, Zhang Q, Tao P, Meng C, et al. Efficacy and Safety of Twelve Anti‐Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta‐Analysis of Randomized Controlled Trials. European Journal of Neurology. 2025. doi:10.1111/ene.70329

BibTeX
@article{Chen2025,
  author = {Chen, Fei-Fei and Wen, Si-Yuan and Chen, Xiang-Ting and Zhang, Qian and Tao, Pan and Meng, Chi and Huang, Jing and Chen, Wei and Zhou, Chang-Qing},
  title = {Efficacy and Safety of Twelve Anti‐Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta‐Analysis of Randomized Controlled Trials},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70329}
}
Kostenlos starten →